ObjectiveTo investigate the clinical effect of Megestrol Acetate in the treatment of endometrial carcinoma.MethodsFrom July 2016 to July 2017,80 patients with endometrial cancer in our hospital were treated.According to their personal will,they were grouped.Among them,39 patients were treated with routine therapy,and the rest 41 patients with endometrial carcinoma treated with Megestrol Acetate on the basis of the control group for intensification.Patients treated by routine therapy was classified into control group,and by intensified treatment was categorized into observation group.The therapeutic effect and improvement of quality of life between the two groups were compared.ResultsAfter treatment,patients with endometrial cancer in the two groups occurred with gastrointestinal reactions to some extent.The incidence of gastrointestinal reaction in the observation group was 9.76%,significantly lower than that in the control group accounting for 35.90%with a statistical difference(P<0.05).The recurrence rate was 7.32%in the observation group and 30.77%in the control group,which was displayed statistical significance after comparison (P<0.05).The scores of quality of life in the observation group were all higher than those in the control group (P<0.05).ConclusionApplication of Megestrol Acetatein the treatment of endometrial cancer obtains a definite clinical value.It not only reduces the patient′s gastrointestinal reaction and recurrence rate,but also markedly improve the quality of life in endometrial cancer patients,which plays a vital role in clinical practice and is worthy of further study and exploration.